



ANUH PHARMA LTD.

CIN: L24230MH1960PLC011586

Registered Office: 3-A, Shivsagar Estate, North Wing, Dr. Annie Besant Road, Worli, Mumbai - 400018
Phone: +91 22 66227575; **Fax:** +91 22 66227600; **Email:** anuh@sk1932.com; **Website:** www.anuhpharma.com

61ST ANNUAL GENERAL MEETING TO BE HELD ON THURSDAY, 19/08/2021 AT 11.00 AM - AGENDA PROCEEDINGS (FLOW OF AGM) & CHAIRMAN'S SPEECH

1) MR. BIPIN SHAH:

Good Afternoon, Ladies and Gentlemen,

I am pleased to welcome you to the 61st Annual General Meeting of Anuh Pharma Ltd. held through Video Conferencing and Other Audio Visual Means in Compliance with the Government of India Directives and to maintain the social distancing norms due to this Covid-19 outbreak. This is in compliance with the Directives of Ministry of Corporate Affairs and Securities and Exchange Board of India.

COVID 19 CRISIS:

Even during COVID 19 crisis, we were successful in running our plant continuously, being an essential drug company.

We are fully complying with requisite safety norms like social distancing, sanitising, temperature monitoring, masking etc.

I would request, Ms. Ashwini Ambrale, our Company Secretary to brief on certain points regarding the participation through Video Conferencing / Other Audio Visual Means & E-voting Procedure.

2) ASHWINI AMBRALE:

Thank you Sir!

This is Ashwini Ambrale, Company Secretary & Compliance Officer of the Company.

I would like to inform you certain points regarding the participation through Video Conferencing / Other Audio Visual Means & E-voting as under:

- 1) As a reminder for smooth conduct of this meeting, the Members will be on the mute mode to avoid any disturbance in the background noise, the audio and the video will be opened when they will speak at the Meeting as per the pre-registration.
- 2) The Shareholder may note that the facility of participation at the AGM through Video Conferencing / Other Audio Visual Means will be made available to at least 1000 members on first come first served basis. If the shareholder is not able to join through the Video, he/she is requested to join through the Audio mode.
- 3) If there is a connectivity problem at the shareholder's end then the Chairman of the Meeting would ask the next speaker to join. Once the speaker connectivity improves the speaker shareholder may again ask to join.
- 4) We would request the speaker shareholder to be slow and loud while asking their questions so as to capture them correctly.
- 5) We request the shareholders to limit their speech to 2-3 minutes.
- 6) During the AGM if the shareholder faces any technical issues, he/she may contact the helpline number as provided in the notice of AGM.

- 7) The Company has taken the requisite steps to enable members to participate and vote on the items being considered at this AGM. The Annual Report for last financial year 2020-21 was sent by an email to all the shareholders who have registered their email IDs with the Company.
- 8) Please note that as per the requirements, the proceedings of the meeting will be recorded and will be available on the website of the Company.
- 9) The Board of Directors of the Company has appointed, Mr. Makarand M. Joshi, Practicing Company Secretary (FCS 5533, CP 3662), or failing him Ms. Kumudini Bhalerao, Practicing Company Secretary (FCS 6667, CP 6690) as the Scrutinizer for conducting the process of remote e-voting and e-voting during the AGM in a fair and transparent manner.
- 10) The procedure for e-Voting on the day of an AGM is same as per the instructions mentioned in the AGM Notice for Remote e-voting.
- 11) Since the Company has provided the e-voting facility to all its Members, there will be no voting by show of hands at the AGM.

Thank you and now I request Mr. Jasvantlal G. Shah, Chairman of the Meeting to take forward the proceedings.

3) MR. JASVANTLAL G. SHAH:

Good afternoon, Ladies and Gentlemen, I would like to welcome all the Shareholders to the 61st Annual General Meeting of Anuh Pharma Ltd. held through Video Conferencing and Other Audio Visual Means.

As the requisite quorum is present I call the Meeting to order.

I would now call upon the Directors, who are on Video Conferencing and Other Audio Visual Means to introduce themselves, starting with Mr. Bipin Shah.

(i) MR. BIPIN SHAH:

Good Afternoon Shareholders, I am Bipin Shah, Vice Chairman of the Company, I am attending this AGM through Video Conferencing from the head office of the Company at Mumbai.

(ii) MR. BHARAT SHAH:

I am Non-Executive Director of the Company, I chair the Stakeholder Relationship Committee of the Company. I am attending this AGM through Video Conferencing from the head office of the Company at Mumbai.

(iii) MR. LALITKUMAR P. SHAH & MR. KETAN SHAH:

We are Non-Executive Directors of the Company, we are attending this AGM through Video Conferencing from our residence at Mumbai.

(iv) MR. ARUN TODARWAL:

I am an Independent Director of the Company and I chair the Nomination and Remuneration Committee of the Company. I am attending this AGM through Video Conferencing from my residence at Mumbai.

(v) MR. H. T. PATEL:

I am an Independent Director of the Company and I am attending this AGM through Video Conferencing from my residence at Vadodara.

(vi) MR. SANDEEP JOSHI:

I am an Independent Director of the Company and I am attending this AGM through Video Conferencing from my residence at Thane.

(vii) DR. MITA DIXIT:

I am an Independent Director of the Company and I am attending this AGM through Video Conferencing from my residence at Mumbai.

(viii) MR. SAMIR SHAH:

I am Non-Executive Director of the Company and I am attending this AGM through Video Conferencing from head office of the Company at Mumbai.

(ix) MR. RITESH SHAH:

I am Joint Managing Director of the Company and I am attending this AGM through Video Conferencing from head office of the Company at Mumbai.

(x) MR. VIVEK SHAH:

I am Joint Managing Director of the Company and I am attending this AGM through Video Conferencing from head office of the Company at Mumbai.

Thank you my colleagues on the Board for introduction.

I would like to now call upon Mr. Darshan Rampariya to introduce himself.

(xi) MR. DARSHAN RAMPARIYA:

Good Afternoon shareholders, this is Darshan Rampariya, Chief Financial Officer of the Company, attending this AGM from the head office of the Company, Mumbai.

MR. JASVANTLAL G. SHAH

We also have our Statutory Auditors, Secretarial Auditors, Cost Auditors and Internal Auditors attending this Meeting through Video Conferencing.

I Thank all the Members for joining this Meeting, I hope the Members are safe and in good health.

Since there is no physical attendance at this Meeting the requirement for appointing the Proxies is not applicable. We have not received any request from corporate members intending to authorize their representatives to participate and vote at the Meeting.

The registers required under the Companies Act, 2013 are available for inspection.

The Notice of this AGM has been sent through electronic mode to the Members who are entitled to receive the same.

With your kind permission ladies and gentlemen, I take the Notice of AGM as read.

Since there are no observations, qualifications or comment by the statutory auditors in their report on financial transaction or matters which have any adverse effect on the functioning of the Company pursuant section 145 of the Companies Act, 2013, the Auditors Report is not required to be read.

I now take this opportunity to read the Chairman's speech.

CHAIRMAN'S SPEECH

Our Operational Revenue for the financial year 2020-21 amounted to Rs. 43,196 lakhs as against Rs. 30,696 lakhs for the previous year, an increase of 40.70%.

Our Profit Before Tax has gone up from Rs 1,916 lakhs to Rs. 3,855 lakhs for this year. I am pleased to inform you that this year we have highest ever growth in top line and bottom line.

For the year under review, the Company had issued Bonus Issue of Equity Shares in the ratio of 1:1 i.e. 1 (One) Equity Shares of face value of Rs. 5/- each for every existing 1 (One) equity share of face value of Rs. 5/- each fully paid by way of capitalization of Free Reserves.

For the year under review, the Company has recommended a Final Dividend of Rs. 1.50 per share i.e. @ 30% (Rs. 2.75/- per share i.e. @ 55% for the previous year) on Equity Shares of face value of Rs. 5/- each of the Company subject to the approval of the shareholders at the AGM. The total dividend outgo shall be Rs. 751.68 lakhs as compared to same amount of Rs. 689.04 lakhs during the previous year.

We are also making best efforts to introduce 2 to 3 new products before the end of the year.

Our new plant already received steady state & as of now there is no capacity constraint.

We are happy to share that 4 new products are under development which are Aripiprazole, Fexofenadine Hcl, Vildagliptin and Allopurinol. Further, Gliclazide performance has been good during last quarter.

We are pleased to inform you that our “NEW EXPANSION PROJECT” is fully operational and due to this increased capacity, we hope to achieve at least 30% additional revenue in 2021-2022.

Global Bulk Drug market:

Three segments - Branded Prescription drugs, Over-the-Counter drugs and Generic Prescription drugs account for a majority of global bulk drug consumption.

The total global bulk drug consumption is expected to reach US Dollars 215 billion by 2022 at a CAGR 6.5% during the forecast period out of which 80% is used for Branded Prescription drugs, 10% for Generic Prescription drugs.

Indian Bulk Drug market:

India is expected to be the 3rd largest global markets for Bulk Drugs with a 7.5% increase in market share. There are 1150 bulk drug units producing about 350 important Bulk Drugs. The market analyst forecast the API (Active Pharmaceutical Ingredients) markets in India to grow at a Compound Annual Growth Rate of 11% over the period of 2021-2025.

MAJOR EVENT SINCE THE CLOSE OF THE YEAR

I am glad to point out that the Company has successfully overcome lean patch with the end of the year on 31st March, 2021.

The Company's performance for 3 months ended on 30th June, 2021 shows topline of Rs. 117 Crores with a bottom line of Rs. 7.11 Crores.

Manufacturing

Anuh Pharma Ltd. is well positioned to service its existing and potential markets through its manufacturing operations at Tarapur in Maharashtra.

The Company enjoys current Good Manufacturing Practices approvals and all the facilities are built and operated according to current Good Manufacturing Practices.

The Company is approved by EDQM (European Directorate for the Quality of Medicines & HealthCare) for the products Erythromycin Base, Erythromycin Ethyl Succinate, & Pyrazinamide. The Company has also got approval from WHO PQ (World Health Organisation Pre-Qualification) Geneva authorities for Pyrazinamide and Sulfadoxine. The Company is also approved by COFEPRIS (Federal Committee for Protection from Sanitary Risks (Comisión Federal para la Protección contra Riesgos Sanitarios),, Mexico for Erythromycin Stearate, Erythromycin Estolate, Erythromycin Ethyl Succinate. The Company has received USFDA (United States Food and Drug Administration) and CEP (Certificate of Suitability) for Ambroxol Hydrochloride during 2020-2021.

The Company has also received plant approvals from several Multi National Companies (MNCs).

Research & Development

During the month of April 2012 the Company had acquired an existing Research & Development Laboratory in Mahape, Navi Mumbai from Spanish Company. This Research & Development Laboratory has three sections, i.e. Analytical Development

Lab, Chemical Synthesis Lab and a Pilot Plant. Each section is updated from time to time with latest equipments and machineries.

This will help us in intensifying our Research & Development activity with a view to enlarge our bulk drugs portfolio.

Before I conclude, I would like to record my gratitude to my colleagues on the Board, for their contribution and support during the year. I also wish to acknowledge the support given by the M/s. Sevantilal Kantilal & Co – our Guardian Company.

I would also like to thank all our Shareholders, Auditors and our Banker, HDFC Bank Ltd., for their patronage and support.

4) AFTER THE CHAIRMAN'S SPEECH, QUESTION/ANSWER SESSION WOULD BE THERE.

{FOR CHAIRMAN'S INFORMATION ONLY - CDSL has been provided with the list of pre-registered speakers, as per the list attached you are requested to take the shareholder's name one by one and CDSL will unmute the shareholder accordingly, one at a time. Each shareholder has been provided 2-3 minutes to ask his/her question. Total 15 shareholders have been pre-registered as a speaker.}

❖ AFTER THE QUESTION ANSWER SESSION,

I now authorise Ms. Ashwini Ambrale, Company Secretary & Compliance Officer to conduct the Voting Procedure.

5) ASHWINI AMBRALE:

Thank you Sir.

Dear Shareholders,

In compliance with the provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014 (as amended) and Regulation 44 of SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015 (as amended), and relevant MCA & SEBI Circulars, the Company has provided the facility of remote e-voting to its Members in respect of the business to be transacted at the AGM. The Company has engaged the services of Central Depository Services (India) Limited (CDSL) to provide the system of remote e-voting as well as the e-voting system on the date of the AGM.

The e-voting facility will remain open for 15 minutes after the conclusion of this Meeting to enable the Members to cast their votes.

The voting results would be announced within 48 hours from the conclusion of the Meeting and the same would be intimated to the BSE Ltd. and uploaded on the website of the Company and CDSL.

❖ I would request Mr. J. G. Shah, Chairman to proceed further with the Meeting.

6) MR. JASVANTLAL G. SHAH:

All the businesses of the Meeting have been completed. I thank the Shareholders for attending the Meeting and for their continued support for showing the keen interest in the Company and seeking clarifications on various matters.

I also thank the Directors to join the Meeting. With your consent, the other Board Members and I would like to leave the Meeting. I request all the Shareholders to stay safe and healthy.

Thank you very much.
